BiCAPPA

BiCAPPA is the first bivalent antiprion ligand. BiCAPPA can decrease infectious conformational form of prion protein (PrPSc) from scrapie-infected cells, with an EC50 of 0.32 μM[1][2].

Product Specifications

CAS Number

[119662-55-4]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Prion Protein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/bicappa.html

Purity

98.35

Solubility

DMSO : 9.52 mg/mL (ultrasonic; adjust pH to 4 with TFA)

Smiles

ClC(C=CC1=C2NCCCN3CCN(CCCNC4=C5C=CC(Cl)=CC5=NC6=C4C=C(OC)C=C6)CC3)=CC1=NC7=C2C=C(OC)C=C7

Molecular Formula

C38H40Cl2N6O2

Molecular Weight

683.67

Precautions

H315, H319, H335

References & Citations

[1]Uliassi E, et, al. 10-Medicinal Chemistry of Hybrids for Neurodegenerative Diseases. Design of Hybrid Molecules for Drug Development. 2017, Pages 259-277.|[2]Bongarzone S, et, al. Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. J Med Chem. 2010 Nov 25;53 (22) :8197-201.